Next Article in Journal
Outcomes of Intercalary Endoprostheses as a Treatment for Metastases in the Femoral and Humeral Diaphysis
Previous Article in Journal
Successful Treatment with Selpercatinib for Ectopic Cushing’s Syndrome Due to Medullary Thyroid Cancer
Previous Article in Special Issue
Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies
Review

Genomics and Immunomics in the Treatment of Urothelial Carcinoma

1
Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, 40138 Bologna, Italy
2
Struttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico ‘Don Tonino Bello’, I.R.C.C.S. Istituto Tumori ‘Giovanni Paolo II’, Viale Orazio Flacco 65, 70124 Bari, Italy
3
Medical Oncology Department, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCSS) Istituto Nazionale dei Tumori, 20133 Milan, Italy
4
Molecular Immunology Unit, Department of Research, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCSS) Istituto Nazionale dei Tumori, 20133 Milan, Italy
5
Johns Hopkins University School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA
6
Department of Internal Medicine, University of South Florida, Tampa, FL 33620, USA
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2022, 29(5), 3499-3518; https://doi.org/10.3390/curroncol29050283
Received: 29 March 2022 / Revised: 8 May 2022 / Accepted: 10 May 2022 / Published: 12 May 2022
Urothelial carcinoma is a complex cancer with genomic immunomic drivers that have prognostic and predictive treatment implications. Identifying potential targetable alterations via next-generation sequencing and RNA sequencing may allow for elucidation of such targets and exploitation with targeted therapeutics. The role of immunotherapy in treating urothelial carcinoma has shown benefit, but it is unclear in which patients immunotherapeutics have the highest yield. Continuing efforts into better identifying which patients may benefit most from targeted therapies, immunotherapies, and combination therapies may ultimately lead to improved outcomes for patients with this disease. View Full-Text
Keywords: genomics; next-generation sequencing; urothelial cancer; immunotherapy genomics; next-generation sequencing; urothelial cancer; immunotherapy
Show Figures

Figure 1

MDPI and ACS Style

Mollica, V.; Massari, F.; Rizzo, A.; Ferrara, R.; Menta, A.K.; Adashek, J.J. Genomics and Immunomics in the Treatment of Urothelial Carcinoma. Curr. Oncol. 2022, 29, 3499-3518. https://doi.org/10.3390/curroncol29050283

AMA Style

Mollica V, Massari F, Rizzo A, Ferrara R, Menta AK, Adashek JJ. Genomics and Immunomics in the Treatment of Urothelial Carcinoma. Current Oncology. 2022; 29(5):3499-3518. https://doi.org/10.3390/curroncol29050283

Chicago/Turabian Style

Mollica, Veronica, Francesco Massari, Alessandro Rizzo, Roberto Ferrara, Arjun K. Menta, and Jacob J. Adashek. 2022. "Genomics and Immunomics in the Treatment of Urothelial Carcinoma" Current Oncology 29, no. 5: 3499-3518. https://doi.org/10.3390/curroncol29050283

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop